On November 21, 2025, XOMA Royalty Corp reported the completion of its acquisition of LAVA Therapeutics' legacy assets, including significant programs with potential milestone payments of approximately $650 million. This event stems from a share purchase agreement initiated on August 3, 2025, and involves future payments contingent on clinical developments.